In the last announcement:
A second interim analysis by the trial’s independent Data Safety Monitoring Board is expected in early November, with completion of patient enrollment expected in December
That would imply that 45% have been dosed by (at least) early-Oct, plus 30 day mortality rate known.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
0.045(2.69%) |
Mkt cap ! $2.133B | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.72 | $1.67 | $496.3K | 293.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 28241 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.72 | 57779 | 5 |
View Market Depth
| Last trade - 10.04am 15/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |